Characterizing medical care by disease phase in metastatic colorectal cancer
- PMID: 21711074
Characterizing medical care by disease phase in metastatic colorectal cancer
Abstract
Objective: To characterize patterns of medical care by disease phase in patients with newly diagnosed metastatic colorectal cancer (mCRC).
Methods: Patients with mCRC newly diagnosed between 2004 and 2008 were selected from a large US national commercially insured claims database and were observed from initial mCRC diagnosis to death, disenrollment, or end of study period (July 31, 2009), whichever occurred first. The observation period was divided into 3 distinct phases of disease: diagnostic, treatment, and death. Within each phase, patterns of medical care were examined by the mutually exclusive service categories of inpatient, emergency department (ED), outpatient office and facility, outpatient pharmacy, chemotherapy, and biologic therapy, as measured by estimation of aggregate and category costs per patient per month.
Results: A total of 6675 patients with newly diagnosed mCRC were analyzed. Mean age was 64.1 years; 55.5% were males. Mean costs per patient per month for diagnostic, treatment, and death phases were $16,895, $8891, and $27,554, respectively. Inpatient care was the primary driver of medical care for both the diagnostic (41.7% of costs) and death (71.4% of costs) phases. The largest category of medical care for the treatment phase was outpatient care (45.0% of costs). Chemotherapy and biologic therapy accounted for 15.6% and 17.6% of costs in the treatment phase, respectively.
Conclusion: Substantial differences in patterns of medical care were found between mCRC disease phases. Inpatient care was the key driver of medical care in the diagnostic and death phases compared with outpatient care in the treatment phase.
Similar articles
-
Characterizing medical care by disease phase in metastatic colorectal cancer.J Oncol Pract. 2011 May;7(3 Suppl):25s-30s. doi: 10.1200/JOP.2011.000304. J Oncol Pract. 2011. PMID: 21886516 Free PMC article.
-
Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.J Med Econ. 2011;14(5):542-52. doi: 10.3111/13696998.2011.596600. Epub 2011 Jul 6. J Med Econ. 2011. PMID: 21728912
-
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.J Med Econ. 2013 Aug;16(8):1071-81. doi: 10.3111/13696998.2013.813513. Epub 2013 Jul 5. J Med Econ. 2013. PMID: 23777222
-
Economics of ramucirumab for metastatic colorectal cancer.Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):733-745. doi: 10.1080/14737167.2016.1259070. Expert Rev Pharmacoecon Outcomes Res. 2016. PMID: 27828732 Review.
-
Cost-effectiveness of new and emerging treatment options for the treatment of metastatic colorectal cancer.Am J Manag Care. 2018 Apr;24(7 Suppl):S118-S124. Am J Manag Care. 2018. PMID: 30207664 Review.
Cited by
-
Angiogenesis in primary colorectal cancer and matched metastatic tissues: Biological and clinical implications for anti-angiogenic therapies.Oncol Lett. 2020 May;19(5):3558-3566. doi: 10.3892/ol.2020.11450. Epub 2020 Mar 6. Oncol Lett. 2020. PMID: 32269630 Free PMC article.
-
The impact of travel time on colorectal cancer stage at diagnosis in a privately insured population.BMC Health Serv Res. 2019 Mar 18;19(1):172. doi: 10.1186/s12913-019-4004-6. BMC Health Serv Res. 2019. PMID: 30885199 Free PMC article.
-
Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.World J Gastroenterol. 2014 May 28;20(20):6102-12. doi: 10.3748/wjg.v20.i20.6102. World J Gastroenterol. 2014. PMID: 24876732 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical